Mario Campone

Mario Campone

UNVERIFIED PROFILE

Are you Mario Campone?   Register this Author

Register author
Mario Campone

Mario Campone

Publications by authors named "Mario Campone"

Are you Mario Campone?   Register this Author

100Publications

4514Reads

17Profile Views

Identification of an immune-suppressed subtype of feline triple-negative basal-like invasive mammary carcinomas, spontaneous models of breast cancer.

Tumour Biol 2020 Jan;42(1):1010428319901052

AMaROC, Oniris (Nantes Atlantic College of Veterinary Medicine, Food Science and Engineering), Nantes, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1010428319901052DOI Listing
January 2020

Androgen receptor and FOXA1 coexpression define a "luminal-AR" subtype of feline mammary carcinomas, spontaneous models of breast cancer.

BMC Cancer 2019 Dec 30;19(1):1267. Epub 2019 Dec 30.

AMaROC, Oniris (Nantes Atlantic College of Veterinary Medicine, Food Science and Engineering), Oniris site Chantrerie, CS40706, 44307, Cedex 3, Nantes, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12885-019-6483-6DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6937649PMC
December 2019

OLFM4 Expression in Ductal Carcinoma In Situ and in Invasive Breast Cancer Cohorts by a SWATH-Based Proteomic Approach.

Proteomics 2019 Nov 8;19(21-22):e1800446. Epub 2019 Aug 8.

Paul Papin ICO Cancer Center, CRCINA, INSERM, 49055, Angers, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/pmic.201800446DOI Listing
November 2019

A comparison of posttraumatic growth changes in breast cancer and melanoma.

Health Psychol 2019 Oct 25;38(10):878-887. Epub 2019 Jul 25.

UMR INSERM 1246 SPHERE, University of Nantes, University of Tours.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1037/hea0000766DOI Listing
October 2019

Feline Invasive Mammary Carcinomas: Prognostic Value of Histological Grading.

Vet Pathol 2019 09 21;56(5):660-670. Epub 2019 May 21.

1 AMaROC, Oniris (Nantes Atlantic College of Veterinary Medicine, Food Science and Engineering), France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/0300985819846870DOI Listing
September 2019

Regenerative nodular hyperplasia after T-DM1: consequences from sinusoidal endothelium damages.

Acta Oncol 2019 Sep 26:1-4. Epub 2019 Sep 26.

Department of Medical Oncology, Institut de Cancérologie de l'Ouest - René Gauducheau , Saint Herblain , France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/0284186X.2019.1670860DOI Listing
September 2019

Pertuzumab for the treatment of breast cancer.

Expert Rev Anticancer Ther 2019 Aug 29:1-11. Epub 2019 Aug 29.

Medical Oncology, Institut de Cancérologie de l'Ouest, René Gauducheau , St Herblain , France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14737140.2019.1596805DOI Listing
August 2019

Imaging necrosis during treatment is associated with worse survival in EORTC 26101 study.

Neurology 2019 06 10;92(24):e2754-e2763. Epub 2019 May 10.

From the University Medical Center & German Cancer Research Center (M.N., F.S., I.H., P.K., M.P., M.B., W.W.), Heidelberg, Germany; EORTC Headquarters (T.G., V.G.), Brussels, Belgium; Brain Tumor Center at Erasmus MC Cancer Institute (J.E.C.B., W.T., M.J.v.d.B.), Rotterdam, the Netherlands; Medical Oncology Department (A.A.B.), AUSL-Bologna-IRCCS Scienze Neurologiche, Bologna, Italy; Haaglanden Medical Center (M.J.B.T.), the Hague; Leiden University Medical Center (M.J.B.T.), the Netherlands; Institut Gustave Roussy (J.D.), Villejuif; Sorbonne Université (A.I.), Inserm, CNRS, UMR S 1127, Institut du Cerveau et de la Moelle Épinière, ICM, AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière-Charles Foix, Service de Neurologie 2-Mazarin, Paris; Institut de Cancerologie de l'Ouest (ICO)-Centre Rene Gauducheau (M.C.), Saint-Herblain, France; Leuven Cancer Institute-KU Leuven (P.M.C.), Belgium; Department of Neurology and Brain Tumor Center (M.W.), University Hospital and University of Zurich, Switzerland; Institut Régional du Cancer Montpellier (M.F.); University of Lille (E.L.R.), U-1192, Inserm; CHU Lille (E.L.R.), General and Stereotaxic Neurosurgery Service; Oscar Lambret Center (E.L.R.), Neurology, Lille, France; Department of Neurology (M.P.), Medical Faculty Mannheim, Heidelberg University, Germany; and Department of Neurology (M.N.), Medical University Innsbruck, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1212/WNL.0000000000007643DOI Listing
June 2019

New UPLC-MS/MS assay for the determination of tamoxifen and its metabolites in human plasma, application to patients.

Future Sci OA 2019 Jun 22;5(5):FSO374. Epub 2019 Mar 22.

Biopathology Department ICO René Gauducheau, Bd J Monod, 44805 Nantes Saint Herblain Cedex, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2144/fsoa-2018-0113DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6554689PMC
June 2019

Alpelisib for -Mutated, Hormone Receptor-Positive Advanced Breast Cancer.

N Engl J Med 2019 05;380(20):1929-1940

From Institut Gustave Roussy, INSERM Unité 981, Université Paris-Sud, Villejuif (F.A.), Institut de Cancérologie de l'Ouest, St. Herblain (M.C.), and Novartis Pharma, Paris (A.-S.L.) - all in France; Hospital Universitario 12 de Octubre, Madrid (E.C.); National Institute of Oncology (G.R.) and Duna Medical Center (Z.P.), Budapest, Hungary; German Breast Group, Neu-Isenburg, and Center for Hematology and Oncology Bethanien, Frankfurt - both in Germany (S.L.); UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco (H.S.R.); Aichi Cancer Center, Nagoya (H.I.), Kanagawa Cancer Center, Yokohama (T.Y.), Saitama Cancer Center, Saitama (K.I.), and National Hospital Organization Hokkaido Cancer Center, Sapporo (M.T.) - all in Japan; Istituto Oncologico Veneto and the Departments of Surgery, Oncology, and Gastroenterology, University of Padua, Padua, Italy (P.C.); Vanderbilt University, Nashville (I.A.M.); Chaim Sheba Medical Center, Tel Hashomer, Israel (B.K.); National Taiwan University Hospital, Taipei (Y.-S.L.); Novartis Pharma, Basel, Switzerland (D.M., C.W.); Novartis Pharmaceuticals, East Hanover, NJ (S.H.); and Massachusetts General Hospital Cancer Center, Boston (D.J.).

View Article

Download full-text PDF

Source
http://www.nejm.org/doi/10.1056/NEJMoa1813904
Publisher Site
http://dx.doi.org/10.1056/NEJMoa1813904DOI Listing
May 2019

Clinical utility of pembrolizumab in the management of advanced solid tumors: an evidence-based review on the emerging new data.

Cancer Manag Res 2019 15;11:4297-4312. Epub 2019 May 15.

Medical Oncology Department, Institut de Cancérologie de l'Ouest, Saint-Herblain 44800, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/CMAR.S151023DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6527794PMC
May 2019

Neratinib in Combination With Trastuzumab for the Treatment of Patients With Advanced HER2-positive Breast Cancer: A Phase I/II Study.

Clin Breast Cancer 2019 04 20;19(2):97-104.e4. Epub 2018 Dec 20.

Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clbc.2018.12.011DOI Listing
April 2019

Pharmacokinetic drug evaluation of abemaciclib for advanced breast cancer.

Expert Opin Drug Metab Toxicol 2019 Feb 5;15(2):85-91. Epub 2019 Jan 5.

a Medical Oncology , Institut de Cancérologie de l'Ouest, René Gauducheau , St Herblain , France.

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/17425255.2019.1
Publisher Site
http://dx.doi.org/10.1080/17425255.2019.1559816DOI Listing
February 2019

Bcl-2 expression and prognostic significance in feline invasive mammary carcinomas: a retrospective observational study.

BMC Vet Res 2019 Jan 10;15(1):25. Epub 2019 Jan 10.

AMaROC, Oniris (Nantes Atlantic College of Veterinary Medicine, Food Science and Engineering), Oniris site Chantrerie, CS40706, 44307, Cedex 3, Nantes, France.

View Article

Download full-text PDF

Source
https://bmcvetres.biomedcentral.com/articles/10.1186/s12917-
Publisher Site
http://dx.doi.org/10.1186/s12917-018-1772-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6329127PMC
January 2019

Phase I trial of afatinib and 3-weekly trastuzumab with optimal anti-diarrheal management in patients with HER2-positive metastatic cancer.

Cancer Chemother Pharmacol 2018 12 22;82(6):979-986. Epub 2018 Oct 22.

Institut Universitaire du Cancer de Toulouse, Oncopôle, 1 avenue Irène Joliot-Curie, 31059, Toulouse Cedex 9, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-018-3689-2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6267664PMC
December 2018

Cutaneous and Gastrointestinal Leukocytoclastic Vasculitis Induced by Palbociclib in a Metastatic Breast Cancer Patient: A Case Report.

Clin Breast Cancer 2018 10 16;18(5):e755-e758. Epub 2018 Aug 16.

Medical Oncology Department, Institut de Cancérologie de l'Ouest, Centre Paul Papin, Angers, France.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15268209183031
Publisher Site
http://dx.doi.org/10.1016/j.clbc.2018.07.006DOI Listing
October 2018

An Update on the Clinical Use of CDK4/6 Inhibitors in Breast Cancer.

Drugs 2018 Sep;78(13):1353-1362

Institut de Cancérologie de l'Ouest, René Gauducheau, St Herblain, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40265-018-0972-9DOI Listing
September 2018

Emerging PARP inhibitors for treating breast cancer.

Expert Opin Emerg Drugs 2018 09 29;23(3):211-221. Epub 2018 Sep 29.

a René Gauducheau , Institut de Cancérologie de l'Ouest , St Herblain , France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14728214.2018.1527900DOI Listing
September 2018

Comment on "How the evolution of multicellularity set the stage for cancer".

Br J Cancer 2018 07 14;119(1):133-134. Epub 2018 May 14.

INSERM U892, IRT-UN, 8 Quai Moncousu, 44007, Nantes Cedex, France.

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41416-018-0091-0
Publisher Site
http://dx.doi.org/10.1038/s41416-018-0091-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6035250PMC
July 2018

Efficacy of palbociclib plus fulvestrant after everolimus in hormone receptor-positive metastatic breast cancer.

Breast Cancer Res Treat 2018 Apr 15;168(2):559-566. Epub 2017 Dec 15.

Medical Oncology Department, Centre René Gauducheau, Institut de Cancérologie de l'Ouest (ICO), Saint-Herblain, France.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s10549-017-4623-8
Publisher Site
http://dx.doi.org/10.1007/s10549-017-4623-8DOI Listing
April 2018

Canine invasive mammary carcinomas as models of human breast cancer. Part 1: natural history and prognostic factors.

Breast Cancer Res Treat 2018 02 30;167(3):635-648. Epub 2017 Oct 30.

Oniris, Nantes Atlantic College of Veterinary Medicine Food Science and Engineering, Animal Cancers, Models for Research in Comparative Oncology (AMaROC) Research Unit, Site de La Chantrerie, 102 Route de Gachet, CS40706, 44307, Nantes, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-017-4548-2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5807494PMC
February 2018

Efficacy of buparlisib in treating breast cancer.

Expert Opin Pharmacother 2017 Dec 1;18(18):2007-2016. Epub 2017 Dec 1.

a Department of Medical Oncology , Institut de Cancérologie de l'Ouest, René Gauducheau , St. Herblain , France.

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/14656566.2017.1
Publisher Site
http://dx.doi.org/10.1080/14656566.2017.1410139DOI Listing
December 2017

MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer.

J Clin Oncol 2017 Nov 2;35(32):3638-3646. Epub 2017 Oct 2.

Matthew P. Goetz, Mayo Clinic, Rochester, MN; Masakazu Toi, Kyoto University, Kyoto, Japan; Mario Campone, Institut de Cancerologie de l'Ouest, Angers Cedex; Olivier Trédan, Centre Léon Bérard, Lyon; Nawel Bourayou, Eli Lilly, Paris, France; Joohyuk Sohn, Yonsei Cancer Center, Seoul; In Hae Park, National Cancer Center, Goyangsi, South Korea; Shani Paluch-Shimon, Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel; Jens Huober, University of Ulm, Ulm, Germany; Shin-Cheh Chen, Chang Gung University Medical College, Taipei, Taiwan; Luis Manso, Hospital Universitario 12 de Octubre; Susana Barriga, Eli Lilly, Madrid, Spain; Orit C. Freedman, Durham Regional Cancer Centre, Oshawa, Ontario, Canada; Georgina Garnica Jaliffe, Grupo Médico CAMINO S.C., Mexico City, Mexico; Tammy Forrester, Martin Frenzel, and Ian C. Smith, Eli Lilly, Indianapolis, IN; and Angelo Di Leo, Hospital of Prato, Prato, Italy.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2017.75.6155
Publisher Site
http://dx.doi.org/10.1200/JCO.2017.75.6155DOI Listing
November 2017

Lomustine and Bevacizumab in Progressive Glioblastoma.

N Engl J Med 2017 11;377(20):1954-1963

From the University Medical Center and German Cancer Research Center, Heidelberg, Germany (W.W., M.B., F.S., I.H., A.D., M.P.); the European Organization for Research and Treatment of Cancer, Brussels (T.G., V.G.), and Leuven Cancer Institute-KU Leuven, Leuven (P.M.C.) - both in Belgium; Haaglanden Medical Center, The Hague (M.T.), Erasmus MC Cancer Institute, Rotterdam (W.T., J.C.B., M.J.B.), and VU University Medical Center, Amsterdam (M.K.) - all in the Netherlands; the Medical Oncology Department, Azienda Unità Sanitaria Locale di Bologna-IRCCS Istituto delle Scienze Neurologiche, Bologna, Italy (A.A.B.); Institut Gustave Roussy, Villejuif (J.D.), Assistance Publique-Hôpitaux de Paris, Hôpitaux Universitaires La Pitié Salpêtrière-Charles Foix, Service de Neurologie 2-Mazarin, INSERM Unité 1127, Centre National de la Recherche Scientifique Unité Mixte de Recherche (UMR) 7225, Sorbonne Universités, University Pierre and Marie Curie 06 UMR S1127, and Institut du Cerveau et de la Moelle Épinière, Paris (A.I.), Institut de Cancerologie de l'Ouest-Centre Rene Gauducheau, Saint-Herblain (M.C.), Institut Régional du Cancer Montpellier, Montpellier (M.F.), and Centre Hospitalier Régional Universitaire de Lille, Lille (E.L.R., F.D.) - all in France; and the Departments of Oncology and Neurology, University Hospital and University of Zurich, Zurich, Switzerland (R.S., M.W.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1707358DOI Listing
November 2017

BCL-X directly modulates RAS signalling to favour cancer cell stemness.

Nat Commun 2017 10 24;8(1):1123. Epub 2017 Oct 24.

Team 8 "Stress adaptation and tumor escape", CRCINA - Institut de Recherche en Santé de l'Université de Nantes-Angers - IRT, BP 70721, 8 quai Moncousu, Nantes, 44007, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41467-017-01079-1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5654832PMC
October 2017

Olaparib for the treatment of breast cancer.

Expert Opin Investig Drugs 2017 Jun 21;26(6):751-759. Epub 2017 Apr 21.

a Medical oncology , Institut de Cancérologie de l'Ouest, René Gauducheau , St Herblain , France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/13543784.2017.1318847DOI Listing
June 2017

Hormonoresistance in advanced breast cancer: a new revolution in endocrine therapy.

Ther Adv Med Oncol 2017 May 14;9(5):335-346. Epub 2017 Mar 14.

Department of Medical Oncology, Institut cancerologie de l'ouest site Paul Papin, France Department of Medical Oncology, Institut cancerologie de l'ouest site René Gauducheau, Saint Herblain, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1758834017693195DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5424863PMC
May 2017

Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study.

J Clin Oncol 2017 Jan 21;35(2):157-165. Epub 2016 Nov 21.

Lucia Nogova, Reinhard Buettner, and Jürgen Wolf, University Hospital Cologne, Cologne; Martin Schuler, University Hospital Essen, and German Cancer Consortium (DKTK), Essen, Germany; Lecia V. Sequist, Massachusetts General Hospital; Geoffrey I. Shapiro, Dana-Farber Cancer Institute, Boston, MA; Jose Manuel Perez Garcia, Vall d'Hebron Institut d'Oncologia, Barcelona; Manuel Hidalgo, Spanish National Cancer Research Centre, Madrid, Spain; Fabrice Andre, Gustave Roussy, Villejuif; Jean-Pierre Delord, Institute Universitaire du Cancer de Toulouse, Toulouse; Philippe A. Cassier, Centre Regional Leon-Berard, Lyon; Mario Campone, Institute de Cancerologie de l'Ouest-René Gauducheau, Nantes, France; Jan H.M. Schellens, Netherlands Cancer Institute, Amsterdam, and Utrecht University, Utrecht, the Netherlands; D. Ross Camidge, University of Colorado, Aurora, CO; Ulka Vaishampayan, Barbara Ann Karmanos Cancer Institute, Detroit, MI; Howard Burris, Sarah Cannon Research Institute, Nashville; G. Gary Tian, The West Clinic, Memphis, TN; Zev A. Wainberg, UCLA School of Medicine, Los Angeles, CA; Wan-Teck Lim, National Cancer Centre, Singapore; Patricia LoRusso, Yale Cancer Center, New Haven, CT; Katie Parker, Xueying Chen, Somesh Choudhury, and Randi Isaacs, Novartis Pharmaceuticals Corporation, East Hanover, NJ; Dale Porter, Novartis Institutes for Biomedical Research, Cambridge, MA; Francois Ringeisen, Novartis Pharma AG; and Diana Graus-Porta, Novartis Institutes for Biomedical Research, Basel, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.67.2048DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6865065PMC
January 2017

Short-term and long-term survival of interval breast cancers taking into account prognostic features.

Cancer Causes Control 2017 01 19;28(1):69-76. Epub 2016 Dec 19.

Loire-Atlantique/Vendée Cancer Registry, Plateau des écoles, 50 route de St Sébastien, 44093, Nantes Cedex 1, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10552-016-0836-0DOI Listing
January 2017

Daunting but Worthy Goal: Reducing the De Novo Cancer Incidence After Transplantation.

Transplantation 2016 Dec;100(12):2569-2583

1 Institut de Transplantation-Urologie-Néphrologie (ITUN), CHU Nantes, Nantes, France. 2 Institut de Cancérologie de l'Ouest (ICO), Nantes, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/TP.0000000000001428DOI Listing
December 2016

Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer.

N Engl J Med 2016 11 7;375(18):1738-1748. Epub 2016 Oct 7.

From the University of Texas M.D. Anderson Cancer Center, Houston (G.N.H.), and Texas Oncology-Baylor Charles A. Sammons Cancer Center and the U.S. Oncology Network, Dallas (J.O.) - all in Texas; Davidoff Center, Rabin Medical Center, Tel Aviv University, Tel Aviv (S.M.S.), and Sheba Medical Center, Ramat Gan (S.P.-S.) - both in Israel; the Sarah Cannon Research Institute (H.A.B., D.Y.), Vanderbilt-Ingram Cancer Center (C.L.A.), and Tennessee Oncology (D.Y.) - all in Nashville; National Cancer Center Singapore, Singapore (Y.-S.Y.); Netherlands Cancer Institute and BOOG Study Center, Amsterdam (G.S.S.); Institut de Cancérologie de l'Ouest/René Gauducheau, Saint-Herblain (M.C.), Institut Gustave Roussy, Université Paris Sud, Villejuif (F.A.), University Hospital of Besançon, Besançon (C.V.), and Centre Léon Bérard, Lyon (T.B.) - all in France; Duke University Medical Center, Durham, NC (K.L.B.); Dana-Farber Cancer Institute, Boston (E.P.W.); University of Ulm, Ulm (W.J.), Onkologische Praxis, Velbert (A.N.), University of Tübingen, Tübingen (E.-M.G.), and Joint Practice for Interdisciplinary Oncology and Hematology, Freiburg (N.M.) - all in Germany; Tom Baker Cancer Centre, Calgary, AB, Canada (S.V.); University of Padua and Istituto Oncologico Veneto, Istituto di Ricovero e Cura a Carattere Scientifico, Padua, Italy (P.C.); Edinburgh Cancer Research Centre, University of Edinburgh, Edinburgh (D.A.C.); Masaryk Memorial Cancer Institute, Brno, Czech Republic (K.P.); Florida Cancer Specialists-Sarah Cannon Research Institute, Fort Myers (L.L.H.); Breast Cancer Research Centre-Western Australia and Curtin University, Perth, Australia (A.C.); Department of Oncology, Vejle Hospital, Vejle, Denmark (E.J.); Arkhangelsk Clinical Oncology Dispensary, Arkhangelsk, Russia (O.B.); Hospital Universitario Virgen de la Victoria, Institute of Biomedical Research in Málaga, Málaga, Spain (E.A.); Oslo University Hospital, Oslo (E.W.); Virginia Cancer Specialists, Arlington (A.M.F.); Taipei Veterans General Hospital, National Yang-Ming University, Taipei, Taiwan (L.-M.T.); Rainier Hematology-Oncology, Northwest Medical Specialties, Puyallup, WA (S.B.); Novartis Pharmaceuticals, East Hanover, NJ (F.X., M.M., C.G., S.H.); and Novartis Pharma, Basel, Switzerland (F.S.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1609709DOI Listing
November 2016

Vinflunine for the treatment of breast cancer.

Expert Opin Pharmacother 2016 Sep 10;17(13):1817-23. Epub 2016 Aug 10.

a Centre René Gauducheau, Institut de Cancérologie de l'Ouest , Boulevard Jacques Monod, Saint-Herblain , France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14656566.2016.1217991DOI Listing
September 2016

Trastuzumab as a preoperative monotherapy does not inhibit HER2 downstream signaling in HER2-positive breast cancer.

Oncol Lett 2016 Sep 20;12(3):2028-2032. Epub 2016 Jul 20.

Cellular Oncology Laboratory, Faculty of Pharmacy, Université de Lorraine, Nancy 54000, France; Centre National pour la Recherche Scientifique, Unité Mixte de Recherche 7039 CRAN, Université de Lorraine, Vandœuvre-lès-Nancy 54500, France; Department of Biopathology, Institut de Cancérologie de Lorraine, Vandœuvre-lès-Nancy 54519, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3892/ol.2016.4891DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4998521PMC
September 2016

PI3K targeting in breast cancer: the end of the beginning?

Lancet Oncol 2016 06 4;17(6):696-697. Epub 2016 May 4.

Centre Léon Bérard, Lyon, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(16)00148-0DOI Listing
June 2016

[Trastuzumab emtansine in the systemic treatment of HER-2-positive breast cancer brain metastases].

Bull Cancer 2016 May 15;103(5):507-10. Epub 2016 Mar 15.

Centre Léon-Bérard, département d'oncologie médicale, 69008 Lyon, France. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bulcan.2016.02.005DOI Listing
May 2016

An open-label, dose-escalation study to evaluate the safety and pharmacokinetics of CEP-9722 (a PARP-1 and PARP-2 inhibitor) in combination with gemcitabine and cisplatin in patients with advanced solid tumors.

Anticancer Drugs 2016 Apr;27(4):342-8

aMedical Oncology Clinic, Institut Jules Bordet, Université Libre de Bruxelles, Brussel, Belgium bInstitut de Cancerologie de l'Ouest, Boulevard Jacques Monod, Nantes St-Herblain Cedex cDrug Development Department, Gustave Roussy Cancer Campus, Villejuif, Cedex dUniversity Paris Sud, Orsay, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CAD.0000000000000336DOI Listing
April 2016

Correlative Analysis of Genetic Alterations and Everolimus Benefit in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From BOLERO-2.

J Clin Oncol 2016 Feb 26;34(5):419-26. Epub 2015 Oct 26.

Gabriel N. Hortobagyi, University of Texas MD Anderson Cancer Center, Houston, TX; David Chen, Tetiana Taran, and David Lebwohl, Novartis Pharmaceuticals, East Hanover, NJ; Martine Piccart and Fabienne Lebrun, Université Libre de Bruxelles, Brussels; Ines Deleu, Oncology Centre, AZ Nikolaas, Sint-Nikolaas, Belgium; Hope S. Rugo, University of California, San Francisco; Ian Anderson, Redwood Regional Oncology Center, Santa Rosa, CA; Howard A. Burris III, Sarah Cannon Research Institute, Nashville, TN; Kathleen I. Pritchard, Sunnybrook Odette Cancer Centre and the University of Toronto, Toronto, Ontario, Canada; Mario Campone, Centre de Recherche en Cancerologie, Nantes-Saint-Herblain; Thomas Bachelot, Centre Léon Bérard, Lyon, France; Shinzaburo Noguchi, Osaka University Medical School; Norikazu Masuda, Osaka National Hospital, Osaka, Japan; Alejandra T. Perez, Memorial Cancer Institute, Hollywood, FL; Mikhail Shtivelband, Ironwood Cancer & Research Centers, Chandler, AZ; Shaker Dakhil, Cancer Center of Kansas, Wichita, KS; Douglas M. Robinson, Wei He, Abhishek Garg, E. Robert McDonald III, Hans Bitter, and Alan Huang, Novartis Institutes for BioMedical Research, Cambridge, MA; and José Baselga, Memorial Sloan-Kettering Cancer Center, New York, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.60.1971DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5070556PMC
February 2016

Pharmacokinetic interaction between pazopanib and cisplatin regimen.

Cancer Chemother Pharmacol 2016 Feb 16;77(2):385-92. Epub 2016 Jan 16.

Institut Claudius-Regaud, IUCT-O, Toulouse, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-015-2953-yDOI Listing
February 2016

Gene-expression signature functional annotation of breast cancer tumours in function of age.

BMC Med Genomics 2015 Nov 23;8:80. Epub 2015 Nov 23.

Bioinfomics unit, Integrated Centre for Oncology - René Gauducheau, Bd J. Monod, Nantes, Saint Herblain Cedex, 44805, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12920-015-0153-6DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4657228PMC
November 2015

The dog as a naturally-occurring model for insulin-like growth factor type 1 receptor-overexpressing breast cancer: an observational cohort study.

BMC Cancer 2015 Oct 8;15:664. Epub 2015 Oct 8.

Oniris, Université Nantes-Angers-Le Mans, Department of Human Health, Biomedical Research and Animal Models, AMaROC Unit and LDHvet laboratory, Nantes Atlantic College of Veterinary Medicine, Food Science and Engineering, Site de la Chantrerie, Route de Gachet, Nantes, F-44307, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12885-015-1670-6DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4598970PMC
October 2015

[Cancer screening practices in elderly with dementia].

Geriatr Psychol Neuropsychiatr Vieil 2015 Jun;13(2):133-40

Pôle hospitalo-universitaire de gérontologie clinique, Centre hospitalo-universitaire de Nantes, Nantes, France.

View Article

Download full-text PDF

Source
http://www.john-libbey-eurotext.fr/medline.md?doi=10.1684/pn
Publisher Site
http://dx.doi.org/10.1684/pnv.2015.0540DOI Listing
June 2015

YM155 potently triggers cell death in breast cancer cells through an autophagy-NF-kB network.

Oncotarget 2015 May;6(15):13476-86

CRCNA, UMR INSERM U892, CNRS 6299, Université de Nantes, Team 8 « Cell Survival and Tumor Escape in Breast Cancers », Institut de Recherche en Santé de l'Université de Nantes, Nantes, France.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4537028PMC
http://dx.doi.org/10.18632/oncotarget.3638DOI Listing
May 2015

Feasibility and cardiac safety of trastuzumab emtansine after anthracycline-based chemotherapy as (neo)adjuvant therapy for human epidermal growth factor receptor 2-positive early-stage breast cancer.

J Clin Oncol 2015 Apr 23;33(10):1136-42. Epub 2015 Feb 23.

Ian E. Krop, Dana-Farber Cancer Institute, Boston, MA; Thomas M. Suter, Bern University Hospital, Bern, Switzerland; Chau T. Dang, Memorial Sloan Kettering Cancer Center, New York; Marc L. Citron, Hofstra North Shore-Long Island Jewish School of Medicine, New Hyde Park, NY; Luc Dirix, Sint-Augustinus Hospital, Antwerp, Belgium; Gilles Romieu, Institut du Cancer de Montpellier Val d'Aurelle, Montpellier; Mario Campone, Institut de Cancérologie de l'Ouest/René Gauducheau, Nantes Saint-Herblain, France; Claudio Zamagni, Policlinico Sant'Orsola-Malpighi Hospital, Bologna; Luca Gianni, San Raffaele Hospital, Milan, Italy; and Na Xu and Melanie Smitt, Genentech, South San Francisco, CA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.58.7782DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5657012PMC
April 2015

Gene-expression molecular subtyping of triple-negative breast cancer tumours: importance of immune response.

Breast Cancer Res 2015 Mar 20;17:43. Epub 2015 Mar 20.

Unité de Bioinfomique, Institut de Cancérologie de l'Ouest - site René Gauducheau, Bd J. Monod, 44805, Saint Herblain Cedex, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13058-015-0550-yDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4389408PMC
March 2015